AUPH — Aurinia Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.85bn
- $1.53bn
- $283.06m
Annual cashflow statement for Aurinia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -181 | -108 | -78 | 5.75 | 287 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 42.1 | 32.8 | 38.5 | 13.7 | 14 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -21.6 | -6.82 | -5.61 | 5.45 | -8.78 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -158 | -79.5 | -33.5 | 44.4 | 136 |
| Capital Expenditures | -1.5 | -0.292 | -0.718 | -0.281 | -0.252 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -102 | -60.3 | -5.99 | 39.5 | -32.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -104 | -60.6 | -6.71 | 39.3 | -32.8 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 221 | 2.43 | -5.13 | -49.1 | -106 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -40.5 | -138 | -45.3 | 34.6 | -3.22 |